GO
Loading...

GlaxoSmithKline PLC

More

  • Merck Lets Its Gardasil Down Tuesday, 3 Feb 2009 | 9:55 AM ET
    Gardasil

    Before Gardasil came to market two to three years ago, some analysts were saying it would become the biggest-selling vaccine in history. But hope and reality have turned out to be two different things.

  • Nissen: Plainspeaking In The Plain-Dealer Wednesday, 21 Jan 2009 | 12:31 PM ET
    Dr. Steven Nissen

    Dr. Steven Nissen, the cardiology chief at the Cleveland Clinic, reportedly remains on the shortlist to possibly become the next FDA Commissioner. Some analysts believe if Dr. Nissen gets the nod there could be a negative knee-jerk reaction in the big pharma sector stocks.

  • Cramer makes the call on viewers' favorite stocks in a special, extended Lightning Round, including PepsiCo, Verizon, Baidu, Boeing and others.

  • Glaxo, Merck & Pfizer: Your Emails Tuesday, 23 Dec 2008 | 1:16 PM ET

    As we head into the holiday break and the bloggable newsflow slows to a trickle, I am digging into the overflowing mailbag while filling in for my vacationing colleague Scott Wapner at the Nasdaq this week.

  • Bristol-Myers To Cut Another 10% of Workforce Tuesday, 16 Dec 2008 | 6:02 PM ET

    Drugmaker Bristol-Myers Squibb said Tuesday it will eliminate another 10 percent of its work force through 2010 as it works to pare costs before it loses patent protection on key drugs.

  • Predictions: 9 For '09 In Pharma Monday, 1 Dec 2008 | 2:00 PM ET

    Look for M&A activity—big and small—a pair of breakthrough drugs and the prospect of government price controls.

  • Where to Hide During the Market Carnage Thursday, 20 Nov 2008 | 10:53 AM ET

    Telcos, pharmas and some media stocks present investment opportunities now, according to Fergus O'Sullivan, managing director at Morgan Stanley.

  • Warren Buffett's Berkshire Hathaway sharply increased its stake in ConocoPhillips this spring and summer, accumulating a total of 84 million shares as of the end of the third quarter on September 30, according to Berkshire's just-released quarterly portfolio filing with the SEC.

  • Job Losses Hitting All Income Levels and Sectors Friday, 7 Nov 2008 | 4:05 PM ET

    The job losses in this downturn are hitting workers across all income levels and job categories, and the cuts are swifter and broader than in past recessions.

  • "Boning Up" On Amgen's D-mab Friday, 7 Nov 2008 | 12:05 PM ET
    AMGEN

    While on the elliptical at the gym the other night I was watching one network newscast and the person on the machine next to me was watching another one.

  • Vanishing Jobs, Stressed Consumers Feed Downturn Friday, 7 Nov 2008 | 10:56 AM ET

    The nation's unemployment rate is at a 14-year high, General Motors reported a massive third-quarter loss and says it may run out of cash next year, and Ford is planning more job cuts after burning through billions of its own.

  • More White and Blue Collar Workers See Pink Slips Thursday, 6 Nov 2008 | 8:01 PM ET

    The job losses in this downturn are hitting workers across all income levels and job categories, and the cuts are swifter and broader than in past recessions.

  • GlaxoSmithKline Trimming US Sales Force by 1,000 Wednesday, 5 Nov 2008 | 11:37 AM ET

    British drugmaker GlaxoSmithKline is restructuring its U.S. operations, starting with reducing its U.S. sales force by 1,000.

  • Stock Picker: Bad Numbers = Good Prospects Tuesday, 4 Nov 2008 | 3:59 PM ET

    John Buckingham of Al Frank Asset Management is ready for a rally — and he names a lot of stocks he expects to ride that rally.

  • Stock Picker: Bad Numbers = Good Prospects (Part 2) Monday, 3 Nov 2008 | 2:27 PM ET

    John Buckingham of Al Frank Asset Management is ready for a rally — and he names a lot of stocks he expects to ride that rally.

  • Opportunity Knocks: Pharma Stocks Thursday, 23 Oct 2008 | 9:13 AM ET

    Pharmaceuticals are priced at a bargain, said Mike Burnick, Weiss Capital Management director of research.

  • Merck Drug Gets Mixed Review from Medical Journal Wednesday, 20 Aug 2008 | 5:03 PM ET

    Two prominent articles in a major medical journal are examining the cost benefits and safety of an expensive, controversial vaccine for a sexually-transmitted disease and cancer.

  • Warren Buffett's Berkshire Hathaway has added a new stake in NRG Energy, according to a just-released portfolio 'snapshot' of its holdings in U.S. publicly-traded stocks as of June 30.  A sharply reduced stake in Anheuser-Busch may have been a bet that InBev's initially unsolicited offer for the U.S. brewer would prove to be unsuccessful.  Conoco-Phillips data is kept "confidential."

  • Britain By The Numbers Wednesday, 13 Aug 2008 | 9:07 AM ET

    Although a longshot in winning the gold in our World Markets Challenge, the UK's FTSE 100 is now less than 1% behind the S&P 500 on the leaderboard.  Here are some key stats on Britain's economy and markets.

  • Lilly, Pfizer & The Economies of ED Thursday, 24 Jul 2008 | 11:25 AM ET

    So, yesterday I posited a theory that the weak American economy might be hurting sales growth of erectile dysfunction drugs. I wondered whether men might be cutting their pills in half and/or not filling their expensive prescriptions if they're having to tighten their belts.